For­mer Al­ler­gan ex­ec heads to Re­vance as it chal­lenges Botox; Mark Pruzan­s­ki sur­rounds him­self with more team­mates

→ Re­vance feels like it has a com­pet­i­tive ad­van­tage over Ab­b­Vie’s block­buster Botox with on­ly bian­nu­al in­jec­tions of its fresh­ly ap­proved Daxxi­fy, as op­posed to the in­jec­tions every three or four months that Botox re­quires. But you come at the king, you best not miss, and as Daxxi­fy hits the mar­ket, Re­vance has now tapped David Hol­lan­der as CMO. Hol­lan­der was pre­vi­ous­ly the chief R&D of­fi­cer at Aerie Phar­ma­ceu­ti­cals, which was sold to Al­con a cou­ple months ago in a $770 mil­lion deal, and he has fa­mil­iar­i­ty with the Botox de­vel­op­er through his 10 years at Al­ler­gan. From 2011-16, he was Al­ler­gan’s VP, glob­al ther­a­peu­tic area head in clin­i­cal de­vel­op­ment for an­te­ri­or seg­ment and con­sumer eye care. The Nashville biotech is al­so test­ing Dax­i­bot­u­linum­tox­i­nA in pa­tients with cer­vi­cal dys­to­nia, among oth­er con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER